Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tectonic Therapeutic (TECX) Cash & Equivalents (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Cash & Equivalents data on record, last reported at $236.9 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 22.65% to $236.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $236.9 million, a 22.65% decrease, with the full-year FY2025 number at $253.8 million, up 79.69% from a year prior.
  • Cash & Equivalents reached $236.9 million in Q1 2026 per TECX's latest filing, down from $253.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TECX hit a ceiling of $306.2 million in Q1 2025 and a floor of $6.3 million in Q3 2023.
  • A 5-year average of $146.0 million and a median of $141.2 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 94.54% in 2023, then soared 2413.35% in 2024.
  • Tracing TECX's Cash & Equivalents over 5 years: stood at $92.6 million in 2022, then tumbled by 68.92% to $28.8 million in 2023, then surged by 390.94% to $141.2 million in 2024, then skyrocketed by 79.69% to $253.8 million in 2025, then dropped by 6.66% to $236.9 million in 2026.
  • Business Quant data shows Cash & Equivalents for TECX at $236.9 million in Q1 2026, $253.8 million in Q4 2025, and $268.4 million in Q3 2025.